查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918194

肿瘤资讯系统市场－2026-2031年预测

Oncology Information Systems Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计肿瘤资讯系统市场将从 2025 年的 31.84 亿美元成长到 2031 年的 47.95 亿美元，复合年增长率为 7.06%。

肿瘤资讯系统（OIS）市场由专门设计的软体平台组成，旨在管理癌症治疗中复杂、数据密集和多学科的工作流程。这些系统如同现代肿瘤诊疗的中枢神经系统，整合患者数据、治疗计划、日程安排和治疗结果跟踪，从而支持高风险治疗领域的临床决策、运营效率和合规性。

核心系统功能和临床集成

肿瘤资讯系统（OIS）并非单一应用程序，而是一套针对肿瘤学特定需求量身定制的整合模组。其核心功能通常包括患者预约、带有肿瘤学专用模板的电子健康记录（EMR）、化疗输入和管理（CPOE）、放射治疗计划和记录管理、临床试验管理以及治疗结果分析。其根本价值在于创建贯穿整个治疗过程的统一患者记录，涵盖从诊断和分期到手术、放射治疗、全身治疗和康復的各个阶段，并确保外科肿瘤医生、内科肿瘤医生、放射肿瘤医生、护士、药剂师和剂量师之间的协作。

主要市场成长驱动因素

市场扩张的根本驱动力是全球癌症负担的日益加重，这导致患者管理的数量和复杂性不断增加。随着病例数量的增长，扩充性且高效的系统至关重要，这些系统能够最大限度地减少错误、规范治疗路径并管理治疗週期中复杂的物流，从而推动了对强大的光学资讯系统（OIS）解决方案的需求。

癌症治疗方法的快速发展是推动组织免疫学（OIS）应用和完善的强大动力。向个人化医疗、生物标记指导治疗以及结合放射疗法、免疫疗法和标靶药物的复杂联合疗法的转变，产生了大量多样化的数据。现代组织免疫学平台对于管理这种复杂性至关重要，它可以追踪基因组检测结果，计算精确的药物剂量和放射治疗方案，并确保安全使用具有独特毒性特征的新型药物。

技术融合是关键的成长方向。互通性标准（例如 HL7、FHIR）、云端运算和资料分析的进步正在改变 OIS 的功能。与诊断成像系统 (PACS)、实验室系统和基因组资料库的集成，能够提供全面的患者观点。将人工智慧 (AI) 和机器学习融入到诸如放射治疗计划中的自动勾画、患者风险分层的预测分析以及临床决策支援等操作中，正推动 OIS 从一种管理工具转变为一种智慧的临床支援工具。

癌症治疗模式正经历着从价值导向到结果导向的巨大转变，这推动了对先进数据收集和分析的需求。结果导向资讯系统（OIS）对于汇总真实世界证据、追踪品质指标以及满足支付方和肿瘤登记机构的要求至关重要，这些报告能够证明治疗的品质和成本效益。

在近期医疗服务模式发展趋势的推动下，远端医疗和远距监测功能的整合已成为关键特性。肿瘤资讯系统（OIS）平台目前支援虚拟会诊、远距病患报告结果（PRO）收集和远端医疗协调，从而扩大了肿瘤学专业知识的覆盖范围，并促进了诊室外的持续护理管理。

市场限制和实施挑战

市场面临系统整合和资源限制的重大障碍。部署和维护线上资讯系统 (OIS) 需要大量的资金投入、专门的 IT 支援和广泛的使用者培训。将 OIS 与医院现有的企业电子健康记录 (EHR)、药房和计费系统整合通常既复杂又耗时，而且成本高昂，并可能导致工作流程中断。

此外，医疗保健基础设施的差异可能会限制其应用：资源匮乏或位于农村地区的医疗机构可能缺乏资金、可靠的高速互联网或先进的 OIS 平台所需的专业 IT 人员，从而在获取这些操作工具方面造成数位落差。

按地区情况分類的采纳模式

北美是一个成熟的大型市场，其特点是肿瘤治疗支出高、早期采用数位医疗技术，以及复杂的监管和报销环境，这需要强大的数据管理能力。主要肿瘤资讯系统供应商、整合的癌症网络以及对医疗资讯技术的巨额投资巩固了该地区的主导地位。

在其他已开发地区和某些高成长市场，这种做法也在不断普及，其动力来自国家癌症控制计划、对集中式癌症中心的投资，以及对改善护理协调和数据收集以进行研发和公共卫生监测的需求。

竞争格局与策略演变

竞争格局包括专业的肿瘤软体公司和设有肿瘤部门的大型医疗IT公司。差异化优势体现在临床功能的深度（特别是先进的放射治疗计划和复杂的全身治疗管理）、无缝的互通性、用户体验以及强大的分析和报告模组。

我们的策略性措施主要集中在开发云端原生平台以减轻诊所的IT负担，利用人工智慧扩展临床工具，以及建立可扩展的模组化系统，使其能够从社区诊所扩展到大规模学术医疗中心。与製药公司和临床研究机构合作，简化临床实验的病患招募和资料管理流程，也是我们日益重要的策略重点。

未来市场趋势

未来，OIS市场的发展方向是提高智慧化程度、互通性并以患者为中心。 OIS将演变为预测性临床作业系统，利用汇总资料来提案个人化治疗方案，并识别有併发症和再入院风险的患者。

增强型病患入口网站和行动整合将赋予病患更多自主权，使其成为自身医疗照护的积极参与者。此外，支持分散式临床试验和产生真实世界证据的组织资讯系统（OIS）的作用也将显着扩展。供应商的成功取决于能否透过提高营运效率、增强病患安全以及提供高品质、互联互通的医疗支持，展现出清晰的投资回报。随着肿瘤学日益数据驱动和多模态，作为支持高效、有效且公平的癌症诊疗服务的关键数位基础设施，OIS市场有望持续成长。

本报告的主要优势：

  • 深入分析：获取主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略进入市场的机会。
  • 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用这些见解，在快速变化的环境中製定策略决策，发展新的商业机会和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

它是用来做什么的？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区分類的收入和预测评估，包括国家/地区
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章 引言

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查数据
  • 先决条件

第三章执行摘要

  • 调查亮点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析

5. 肿瘤资讯系统市场（依产品划分）

  • 介绍
  • 解决方案
  • 专业服务

6. 按应用分類的肿瘤资讯系统市场

  • 介绍
  • 肿瘤内科
  • 放射肿瘤学
  • 外科肿瘤学

7. 按最终用户分類的肿瘤资讯系统市场

  • 介绍
  • 医院和诊断影像中心
  • 政府机构
  • 研究设施

8. 各地区肿瘤资讯系统市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十章：公司简介

  • Varian
  • RaySearch Laboratories
  • Seimens Healthineers
  • Elekta
  • Chiuhomed
  • Mckesson
  • IQVIA
  • Cerner
  • Philips
  • GE Healthcare
简介目录
Product Code: KSI061616023

Oncology Information Systems Market is expected to grow at a 7.06% CAGR, increasing from USD 3.184 billion in 2025 to USD 4.795 billion in 2031.

The oncology information systems (OIS) market comprises specialized software platforms designed to manage the complex, data-intensive, and multidisciplinary workflow of cancer care. These systems function as the central nervous system of modern oncology practices, integrating patient data, treatment planning, scheduling, and outcomes tracking to support clinical decision-making, operational efficiency, and compliance in a high-stakes therapeutic area.

Core System Function and Clinical Integration

An OIS is not a singular application but an integrated suite of modules tailored to oncology's unique demands. Core functionalities typically include patient scheduling, electronic medical records (EMR) with oncology-specific templates, chemotherapy order entry and management (CPOE), radiation therapy planning and record-keeping, clinical trial management, and outcomes analysis. Its fundamental value lies in creating a unified patient record across the care continuum-from diagnosis and staging through surgery, radiation, systemic therapy, and survivorship-ensuring coordination among surgical, medical, and radiation oncologists, nurses, pharmacists, and dosimetrists.

Primary Market Growth Drivers

Market expansion is fundamentally driven by the rising global burden of cancer, which increases the volume and complexity of patient management. A growing caseload necessitates scalable, efficient systems to minimize errors, standardize care pathways, and manage the intricate logistics of treatment cycles, fueling demand for robust OIS solutions.

The rapid evolution of cancer therapeutics is a powerful catalyst for OIS adoption and sophistication. The shift toward personalized medicine, biomarker-driven therapy, and complex multimodal regimens (combining radiation, immunotherapy, and targeted agents) generates vast, heterogeneous data. Modern OIS platforms are essential for managing this complexity, tracking genomic results, calculating precise drug doses and radiation plans, and ensuring the safe administration of novel agents with unique toxicity profiles.

Technological convergence is a key growth vector. Advancements in interoperability standards (e.g., HL7, FHIR), cloud computing, and data analytics are transforming OIS capabilities. Integration with diagnostic imaging (PACS), laboratory systems, and genomic databases creates a holistic patient view. The incorporation of artificial intelligence and machine learning for tasks like auto-contouring in radiation planning, predictive analytics for patient risk stratification, and clinical decision support is moving OIS from administrative tools to intelligent clinical aids.

The structural shift toward value-based and outcomes-focused cancer care models reinforces the need for sophisticated data capture and analysis. OIS enables the aggregation of real-world evidence, tracking of quality metrics, and reporting required by payers and tumor registries, making it indispensable for demonstrating care quality and cost-effectiveness.

The integration of telemedicine and remote monitoring capabilities, accelerated by recent healthcare delivery trends, has become a critical feature. OIS platforms now support virtual consultations, remote patient-reported outcome (PRO) collection, and telehealth coordination, extending the reach of oncology expertise and facilitating continuous care management outside the clinic.

Market Restraints and Implementation Challenges

The market faces significant barriers related to system integration and resource constraints. Implementing and maintaining an OIS requires substantial capital investment, dedicated IT support, and extensive user training. Integrating the OIS with a hospital's existing enterprise EHR, pharmacy, and billing systems is often a complex, time-consuming, and costly undertaking, potentially leading to workflow disruptions.

Furthermore, disparities in healthcare infrastructure can limit adoption. Resource-constrained or rural facilities may lack the financial means, reliable high-speed internet, or specialized IT personnel required for advanced OIS platforms, creating a digital divide in access to these operational tools.

Geographic Landscape and Adoption Patterns

North America represents a mature and dominant market, characterized by high cancer care expenditure, early adoption of digital health technologies, and a complex regulatory and reimbursement environment that necessitates robust data management. The presence of leading OIS vendors, integrated cancer networks, and significant investment in healthcare IT consolidates the region's leadership.

Other developed regions and select high-growth markets are also advancing adoption, driven by national cancer control plans, investments in centralized cancer centers, and the need to improve care coordination and data collection for research and public health monitoring.

Competitive Landscape and Strategic Evolution

The competitive environment includes specialized oncology software firms and large healthcare IT corporations with dedicated oncology divisions. Differentiation is achieved through depth of clinical functionality-particularly in advanced radiation therapy planning and complex systemic therapy management-seamless interoperability, user experience, and robust analytics and reporting modules.

Strategic initiatives focus on developing cloud-native platforms to reduce IT burden on clinics, expanding AI-powered clinical tools, and creating modular systems that can scale from community practices to large academic centers. Partnerships with pharmaceutical companies and clinical research organizations to streamline trial recruitment and data management are also a growing strategic focus.

Future Market Trajectory

The future trajectory of the OIS market is oriented toward greater intelligence, interoperability, and patient-centricity. OIS will evolve into predictive clinical operating systems, leveraging aggregated data to suggest personalized treatment pathways and identify patients at risk for complications or hospital readmission.

Enhanced patient portals and mobile integration will empower patients as active participants in their care. Furthermore, the role of OIS in enabling decentralized clinical trials and real-world evidence generation will expand significantly. Success for vendors will hinge on demonstrating a clear return on investment through improved operational efficiency, enhanced patient safety, and support for high-quality, coordinated care. As oncology becomes increasingly data-driven and multimodal, the OIS market is poised for sustained growth as the essential digital infrastructure underpinning effective, efficient, and equitable cancer care delivery.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Oncology Information Systems Market Segmentation:

  • By Product
  • Solutions
  • Professional Services
  • By Application
  • Medical Oncology
  • Radiation Oncology
  • Surgical Oncology
  • By End-User
  • Hospitals & Diagnostic Imaging Centers
  • Government Institutions
  • Research Facilities
  • By Geography
  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. ONCOLOGY INFORMATION SYSTEMS MARKET, BY PRODUCT

  • 5.1. Introduction
  • 5.2. Solutions
  • 5.3. Professional Services

6. ONCOLOGY INFORMATION SYSTEMS MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Medical Oncology
  • 6.3. Radiation Oncology
  • 6.4. Surgical Oncology

7. ONCOLOGY INFORMATION SYSTEMS MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals & Diagnostic Imaging Centers
  • 7.3. Government Institutions
  • 7.4. Research Facilities

8. ONCOLOGY INFORMATION SYSTEMS MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Varian
  • 10.2. RaySearch Laboratories
  • 10.3. Seimens Healthineers
  • 10.4. Elekta
  • 10.5. Chiuhomed
  • 10.6. Mckesson
  • 10.7. IQVIA
  • 10.8. Cerner
  • 10.9. Philips
  • 10.10. GE Healthcare